Release Summary

Tarveda announces Phase 1 clinical trial of PEN-221 in neuroendocrine tumors and small cell lung cancer. PEN-221 is a Pentarin - miniaturized, highly specific drug conjugate.

Tarveda Therapeutics, Inc.